Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

Biological Chemistry

Volumn 390, Issue 1, 2009, Pages 75-80

  Irwin, Nigel ^a   McClean, Paula L ^a   Patterson, Steven ^a   Hunter, Kerry ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Active immunisation; Gastric inhibitory polypeptide (GIP); GIP antibody; Glucose homeostasis; Passive immunisation

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE HOMEOSTASIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; BLOOD GLUCOSE; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HOMEOSTASIS; HUMANS; IMMUNIZATION, PASSIVE; INSULIN; MALE; MICE; OBESITY; TIME FACTORS; VACCINATION;

ANIMALIA; MUS;

EID: 58249097085     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2009.002     Document Type: Article

References (29)

1. Althage, M.C., Ford, E.L., Wang, S., Tso, P., Polonsky, K.S., and Wice, B.M. (2008). Targeted ablation of GIP-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283, 18365-18376.
2. Bailey, C.J., Flatt, P.R., and Atkins, T.W. (1982). Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6, 11-21.
3. Bailey, C.J., Flatt, P.R., Kwasowski, P., Powell, C.J., and Marks, V. (1986). Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol. (Copenh.) 112, 224-229.
4. Brown, J.C. (1994). Enteroinsular axis. In: Gut Peptides Biochemistry and Physiology, J.H. Walsh and G.J. Dockray, eds. (New York, USA: Raven Press), pp 765-784.
5. Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).
6. Ebert, R., Illmer, K., and Creutzfeldt, W. (1979). Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 76, 515-523.
7. Eckel, R.H., Fujimoto, W.Y., and Brunzell, J.D. (1979). Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 28, 1141-1142.
8. Flatt, P.R. and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577.
9. Flatt, P.R., Bailey, C.J., Kwasowski, P., Page, T., and Marks, V. (1984). Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J. Endocrinol. 101, 249-256.
10. Gault, V.A., O'Harte, F.P., Harriott, P., and Flatt, P.R. (2002). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426.
11. Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P., O'Harte, F.P., and Flatt, P.R. (2005). Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446.
12. Gault, V.A., McClean, P.L., Cassidy, R.S., Irwin, N., and Flatt, P.R. (2007). Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50, 1752-1762.
13. Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., and Drucker, D.J. (2007). Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 117, 143-152.
14. 3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50, 1532-1540.
15. Kim, S.J., Nian, C., and McIntosh, C.H. (2007). Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J. Biol. Chem. 282, 8557-8567.
16. Lean, M. and Finer, N. (2006). ABC of obesity. Management: part II - drugs. Br. Med. J. 333, 794-797.
17. McClean, P.L., Irwin, N., Cassidy, R.S., Holst, J.J., Gault, V.A., and Flatt, P.R. (2007). GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293, E1746-1755.
18. McKillop, A.M., McCluskey, J.T., Boyd, A.C., Mooney, M.H., Flatt, P.R., and O'Harte, F.P. (2000). Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. J. Endocrinol. 167, 153-163.
19. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742.
20. Mokdad, A.H., Giles, W.H., Bowman, B.A., Mensah, G.A., Ford, E.S., Smith, S.M., and Marks, J.S. (2004). Changes in health behaviors among older Americans, 1990 to 2000. Public Health Rep. 119, 356-361.
21. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., and Creutzfeldt, W. (1993). Preserved incretin activity of glucagon-like peptide 1 w7-36 amidex but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307.
22. Oben, J., Morgan, L., Fletcher, J., and Marks, V. (1991). Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 130, 267-272.
23. O'Harte, F.P., Gault, V.A., Parker, J.C., Harriott, P., Mooney, M.H., Bailey, C.J., and Flatt, P.R. (2002). Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45, 1281-1291.
24. Pamir, N., Lynn, F.C., Buchan, A.M., Ehses, J., Hinke, S.A, Pospisilik, J.A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C.H., and Pederson, R.A. (2003). Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 284, E931-939.
25. Perley, M.J. and Kipnis, D.M. (1967). Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 46, 1954-1962.
26. Ross, S.A. and Dupré, J. (1978). Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 27, 327-333.
27. Stevens, J.F. (1971). Determination of glucose by an automatic analyser. Clin. Chem. Acta 32, 199-201.
28. Vella, A. and Rizza, R.A. (2004). Extrapancreatic effects of GIP and GLP-1. Horm. Metab. Res. 36, 830-836.
29. Yip, R.G., Boylan, M.O., Kieffer, T.J., and Wolfe, M.M. (1998). Functional GIP receptors are present on adipocytes. Endocrinology 139, 4004-4007.